PT. Dataindo Inti Swakarsa

          PT. Dataindo Inti Swakarsa
Membership | FAQ | About | Contact | Home 

Indonesia Companies - Indonesia Industry Reports - Indonesia Trade Reports - Indonesia Bilateral Reports
SEARCH  
MEMBER LOGIN    

Products

Latest Updates

Related Reports

Other Related Reports

Industry News
Kimia Farma dividend of Rp.27.7 billion: http://www.tempointeraktif.com//hg/bisnis/2011/06/15/brk,20110615-340990,id.html 15 June 2011


State-owned enterprises (SOEs) operating in the pharmaceutical sector PT Kimia Farma (Persero) Tbk, a dividend of Rp.27.7 billion from fiscal year 2010 or about 5 percent per share, the remaining net profit will be used for the development of the Company's investment of Rp.105 billion, and about 2 percent of net profits will be used for environmental programs and establish partnerships that run the Company.

In 2011 we expect the financial performance will be better because the pharmaceutical industry experiencing growth and improved margins. This is due to the strengthening of the rupiah and rising prices of health budgets, so the base price is better. The government has also raised the price of generic drugs so that expected revenue will increase. The Company will also prioritize the production of drugs to Aids or Hepatitis margin is better because it is not much competition.
Breakthrough in National Pharmaceutical Industry: www.ristek.go.id, 30 April 2009


Drug Basic Material has been a strategic independence issue for the national pharmaceutical industry as 95 percent of the basic materials is still imported. On 29 April 2009, the State Ministry of Research and Technology held a focus group discussion theme "Actualizing Independence in the National Pharmaceutical Industry". Results from the meeting would be used as input to design the Research, Development and Implementation to Support the Development of Indonesia's Pharmaceutical Industry.
 

Medicinal and Pharmaceutical Products Manufacturing in Indonesia
Indonesia Industry Report and Market Research
April 16, 2016
Industry Code : C35221
Forecast to : 2020

Definition
Medicinal and Pharmaceutical Products Manufacturing in Indonesia Manufacturing drugs, medicinal chemicals or other pharmaceutical products, except herbal medicine, for human or veterinary use.
Activities
The primary activities of firms in this industry are:
- Ethical products.
- OTC products.
- Consumer Health.
- Household Insecticides.
- Household Pesticides.
- Antitoxin.
- Barrier cream.
- Contraceptive.
- Medical Gas.
- Morphine Drug.
- Ointment.
- Pharmaceutical preparation.
- Plasters and Bandages.
- Serum and Vaccines.
- Toiletries.
- Vitamin products.
PT. Dataindo Inti SwakarsaTelp : (62 - 21) 719 3832
3rd Floor, Gapura Raya BuildingTelp : (62 - 21) 719 3834
Jl. Bangka Raya No. 4, Pela Mampang Email : info@disb2b.com
Jakarta 12720, Indonesia
Chapter Headings US $ Select All
Industry Outlook 60.50
Key Statistics 60.50
Market Characteristics 36.30
Segmentation 36.30
Industry Conditions 60.50
Industry Performance 60.50
Key Competitors 60.50
Key Factors 27.50
News
Bayer Schering Pharma Strengthens Position in Specialty Care 0.39
Dexa Medica Provides Free Medications 0.39
Foreign Investor's Interest in Pharmacy Still Large 0.39
Darya-Varia Soon To Go Private 0.39
Darya-Varia Soon To Go Private 0.39
Pharmaceutical Industry Not Ready for Liberalization 0.39
Merck Complains about High Costs 0.39
H5N1 Vaccine Production Awaits MoU 0.39
Indofarma Revises Income Target 0.39
Bio Farma Will Produce Avian Flu Vaccination 0.39
Pharmaceutical Products Should be Free of VAT 0.39
Bio Farma Prepares 66.2 Million Dosages of Polio Vaccine 0.39
KF and Indofarma's Merger Appraisal Done 0.39
Dexa Builds Rp.35 Billion Antibiotics Factory 0.39
Pyridam's Sales Increase 0.39
New Blue Chip 0.39
Sanbe Operates Sterile Material Factory 0.39
Indofarma’s Sales Plummets 0.39
Kalbe, Dankos, and Enseval Merger Approved 0.39
Tamiflu To Boost Kimia Farma’s Sales 0.39
Kalbe’s Value Increase After Merger 0.39
Merger of Three Pharmaceutical Companies 0.39
Dankos Projects Sales Increase 0.39
PT Dankos Projects Sales to Increase by 30 Percent 0.39
Kalbe Farma's Meeting with FRN Creditors to be Held Next Month 0.39
Dankos Pays Obligation Debt 0.39
Indofarma's Capex Rp.8 Billion 0.39
Kimia Farma Eyes Tamiflu Retail Operations 0.39
Kalbe Guarantees That There'll be No Lay Offs 0.39
Kalbe Reaches Target Sales 0.39
Kalbe Yet to Revise 2005's Target 0.39
BPPT and Dexa Co-operates 0.39
The 2005 Konicare Healthy and Photogenic Baby Competition 0.39
Kalbe Farma Hopes for Dollar Stability 0.39
Kimia Farma Revises Net Profit Target 0.39
Dankos Develops Export Market 0.39
Kimia Farma's Income Will Rise 0.39
Dankos' Performance for Semester I Improves 0.39
Indofarma Submits Financial Report by the End of August 0.39
Creditors are Asked to Approve Kalbe's Merger 0.39
Kalbe Farma Prepares US$ 60 Million 0.39
Medicine Basic Commodities Prices Remain Stable 0.39
PT. Indofarma Ready to Boost Factory Utilisation Above 50 Percent 0.39
40 percent budget of Health Insurance for the Poor to be allocated for Medicines 0.39
Government to Merge PT. Kimia Farma and PT. Indofarma 0.39
Health Ministry Again Reduce Price of Essential Generic Medicines 0.39
Phapros’ Partnership Fund Rp.1.8 Billion 0.39
Chemical and Pharmaceutical Industry Attracts More Foreign Investors 0.39
Tempo Scans Cancels to Take Over Indofarma's Subsidiary 0.39
2 Chinese Pharmaceutical Companies to Invest in Indonesia 0.39
Phapros Develops Herbal Medicine 0.39
Pyridam Farma Will Not Share Dividend This Year 0.39

Report Content

The Medicinal and Pharmaceutical Products Manufacturing industry in Indonesia research report contain trend analysis, statistics, market size information, industry growth rates as well as major competitors.

Major market segments are identified and also those forces affecting demand and supply within this industry. Performance analysis includes emerging industry trends as well as recent results and performance of each key company. Drawing on the depth of information DIS also provides 5 year forecasts for this industry.

The comprehensive study also examines details such as the barriers to entry, operating cost structure, technology & systems and domestic & international markets. Tables and statistics include: Industry revenue, exports, imports, wages and number of companies in the industry, Industry growth and geographic regional data.


KEY STATISTICS 2004 2005 2006 2007 2008
Industry Revenue 107,942 104,367 131,689 158,085 169,151 Rp.Billion
Industry Gross Product 7,016 6,784 8,560 10,276 10,995 Rp.Billion
Number of Establishments 110 120 130 130 130 Units
Employment 109,600 101,200 85, 81,000 85,400 Units
Exports 2,856 3,457 6,481 6,521 7,820 Rp.Billion
Imports 10,926 10,899 25,482 30,419 35,880 Rp.Billion
Total Wages 1,425 1,316 1,114 1,010 1,109 Rp.Billion
Domestic Demand 116,012 111,809 150,690 181,983 197,211 Rp.Billion
The data above is sample data only

COST STRUCTURE % OF SALES COST STRUCTURE % OF SALES
Cost of Goods Sold 67.13 Gross Profit 32.87
Operating Expense 21.5 Profit (Loss) Before Tax 11.36
Administration 1.58 Depreciation 0.56
Electricity 0.66 Freight 1.99
Fuel, Parking, Toll & Retribution 1.62 Interest 3.09
Land and Building Rental 2.74 Marketing 2.69
Repairs and Maintenance 0.54 Service Fee 0.7
Staff Welfare Allowance 1.38 Other Expenses 0.92
Stationery & Inventory 0.48 Telephone 0.8
Utensils and Equipment 1.24 Wages and Salaries 0.5
The data above is sample data only

ESTABLISHMENTS IN (%) ESTABLISHMENTS IN (%)
Central Java 13.4 DKI Jakarta 6.5
East Java 22.4 North Sumatra 17.9
Papua 2.0 Bali 3.0
South Sulawesi 6.0 West Java 28.8
The data above is sample data only
TOTAL PRICE (US$)(RP)
Price 500.006.250.000
Payment Method
Credit Card
Bank Transfer in US$
Bank Transfer in RP
Buy Now

 
Selective Member`s Discount Price
US$
To become a Selective Member
Register
Table of Contents
About this Report
Outlook
Key Statistics
Segmentation
Market Characteristics
Industry Conditions
Key Factors
Key Competitors
Industry Performance